{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:30:34Z","timestamp":1790386234758,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Granulomatous\u2013lymphocytic interstitial lung disease (GLILD) is a rare, potentially severe pulmonary complication of common variable immunodeficiency disorders (CVID). Informative clinical trials and consensus on management are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>The European GLILD network (e-GLILDnet) aims to describe how GLILD is currently managed in clinical practice and to determine the main uncertainties and unmet needs regarding diagnosis, treatment and follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The e-GLILDnet collaborators developed and conducted an online survey facilitated by the European Society for Immunodeficiencies (ESID) and the European Respiratory Society (ERS) between February\u2013April 2020. Results were analyzed using SPSS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and sixty-one responses from adult and pediatric pulmonologists and immunologists from 47 countries were analyzed. Respondents treated a median of 27 (interquartile range, IQR 82\u2013maximum 500) CVID patients, of which a median of 5 (IQR 8\u2013max 200) had GLILD. Most respondents experienced difficulties in establishing the diagnosis of GLILD and only 31 (19%) had access to a standardized protocol. There was little uniformity in diagnostic or therapeutic interventions. Fewer than 40% of respondents saw a definite need for biopsy in all cases or performed bronchoalveolar lavage for diagnostics. Sixty-six percent used glucocorticosteroids for remission-induction and 47% for maintenance therapy; azathioprine, rituximab and mycophenolate mofetil were the most frequently prescribed steroid-sparing agents. Pulmonary function tests were the preferred modality for monitoring patients during follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These data demonstrate an urgent need for clinical studies to provide more evidence for an international consensus regarding management of GLILD. These studies will need to address optimal procedures for definite diagnosis and a better understanding of the pathogenesis of GLILD in order to provide individualized treatment options. Non-availability of well-established standardized protocols risks endangering patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2020.606333","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T06:06:56Z","timestamp":1606370816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Managing Granulomatous\u2013Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey"],"prefix":"10.3389","volume":"11","author":[{"given":"Annick A. J. M.","family":"van de Ven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago M.","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan O.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Condliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rre","family":"Fevang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Gennery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomeen","family":"Haerynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Jolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Malphettes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Meignin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Milota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"van Montfrans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Prasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Renzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Warnatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International Consensus Document (ICON): Common Variable Immunodeficiency Disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2009.10.013","article-title":"Primary immunodeficiencies: 2009 update","volume":"124","author":"Notarangelo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jaci.2011.02.039","article-title":"Genome-wide association identifies diverse causes of common variable immunodeficiency","volume":"127","author":"Orange","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fimmu.2018.00636","article-title":"Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond","volume":"9","author":"de Valles-Ib\u00e1\u00f1ez","year":"2018","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(15)00202-7","article-title":"Lung disease in primary antibody deficiency","volume":"3","author":"Verma","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2004.05.057","article-title":"Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency","volume":"114","author":"Bates","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2249.2011.04425.x","article-title":"Airway and interstitial lung disease are distinct entities in paediatric common variable immunodeficiency","volume":"165","author":"van de Ven","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2017.01.021","article-title":"British Lung Foundation\/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders","volume":"5","author":"Hurst","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"e122728","DOI":"10.1172\/jci.insight.122728","article-title":"BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency","volume":"4","author":"Maglione","year":"2019","journal-title":"JCI Insight"},{"key":"B10","doi-asserted-by":"crossref","first-page":"b866","DOI":"10.1136\/bmj.b866","article-title":"Written informed consent and selection bias in observational studies using medical records: systematic review","volume":"338","author":"Kho","year":"2009","journal-title":"BMJ"},{"key":"B11","article-title":"Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings","volume":"3","author":"Maglione","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.7757-16","article-title":"Intravenous immunoglobulin monotherapy for granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency","volume":"56","author":"Hasegawa","year":"2017","journal-title":"Internal Med"},{"key":"B13","first-page":"100965","article-title":"An unusual mimicker of asthma in an active duty army physician: Common variable immunodeficiency presenting as granulomatous lymphocytic interstitial lung disease","volume":"29","author":"Askin","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/904675","article-title":"Granulomatous lymphocytic interstitial lung disease in infancy","volume":"21","author":"Adeleye","year":"2014","journal-title":"Can Respir J"},{"key":"B15","article-title":"Treatment Strategies for GLILD in Common Variable Immunodeficiency: a Systematic Review","year":"2020","journal-title":"Front Immunol"},{"key":"B16","first-page":"PA1408","article-title":"Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)","volume":"54","author":"Gkrepi","year":"2019","journal-title":"Eur Respir J"},{"key":"B17","article-title":"Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency","volume":"7","author":"Cereser","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.18176\/jiaci.0450","article-title":"Rituximab as a single agent for granulomatous lymphocytic interstitial lung disease in common variable immune deficiency","volume":"29","author":"Tessarin","year":"2019","journal-title":"J Invest Allergol Clin Immunol"},{"key":"B19","article-title":"Successful rituximab treatment of granulomatous\/lymphocytic interstitial lung disease in common variable immunodeficiency. [Czech]","volume":"67","author":"Kralickova","year":"2018","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.08.022","article-title":"Tertiary lymphoid neogenesis is a component of pulmonary lymphoid hyperplasia in patients with common variable immunodeficiency","volume":"133","author":"Maglione","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2019.01.034","article-title":"Rituximab Monotherapy for Common Variable Immune Deficiency-Associated Granulomatous-Lymphocytic Interstitial Lung Disease","volume":"155","author":"Ng","year":"2019","journal-title":"Chest"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-012-9755-3","article-title":"Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID)","volume":"33","author":"Chase","year":"2013","journal-title":"J Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fped.2019.00105","article-title":"Treatment-Responsive Granulomatous-Lymphocytic Interstitial Lung Disease in a Pediatric Case of Common Variable Immunodeficiency","volume":"7","author":"Tillman","year":"2019","journal-title":"Front Pediatr"},{"key":"B24","article-title":"Management of granulomatous lymphocytic interstitial lung disease in a patient with common variable immune deficiency","volume":"2016","author":"Pathria","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-016-0320-3","article-title":"X-linked Inhibitor of Apoptosis Complicated by Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) and Granulomatous Hepatitis","volume":"36","author":"Steele","year":"2016","journal-title":"J Clin Immunol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pcl.2016.08.007","article-title":"Immunodeficiency Presenting as an Undiagnosed Disease","volume":"64","author":"Routes","year":"2017","journal-title":"Pediatr Clinics North Am"},{"key":"B27","article-title":"Serum IL-12 and soluble IL-2 receptor levels as possible biomarkers of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency: A case report","volume":"3","author":"Vitale","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.07.021","article-title":"Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency","author":"Verbsky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11882-018-0769-7","article-title":"Granulomatous-Lymphocytic Interstitial Lung Disease in 22q11.2 Deletion Syndrome: A Case Report and Literature Review","volume":"18","author":"Sood","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1111\/cei.12856","article-title":"FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)","volume":"187","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s10875-012-9778-9","article-title":"Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients","volume":"33","author":"Boursiquot","year":"2013","journal-title":"J Clin Immunol"},{"key":"B32","doi-asserted-by":"crossref","first-page":"2000089","DOI":"10.1183\/13993003.00089-2020","article-title":"Interstitial lung disease in primary immunodeficiency: towards a brighter future","volume":"55","author":"Hurst","year":"2020","journal-title":"Eur Respir J"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-018-0488-9","article-title":"Immunologist\u2019s Perspectives on Assessment and Management of Lung Disease in CVID: a Survey of the Membership of the Clinical Immunology Society and the European Society for Immunodeficiencies","volume":"38","author":"Akhter","year":"2018","journal-title":"J Clin Immunol"},{"key":"B34","first-page":"Cd005590","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B35","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2020.01245","article-title":"Low IgA Associated With Oropharyngeal Microbiota Changes and Lung Disease in Primary Antibody Deficiency","volume":"11","author":"Berbers","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.606333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T06:07:02Z","timestamp":1606370822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.606333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2020.606333"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.606333","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"article-number":"606333"}}